Roche, Donald Trump and drug pricing
Digest more
Sanofi said it will invest at least $20 billion in the US through 2030, joining other pharmaceutical companies boosting their American operations as President Donald Trump threatens to impose tariffs and cut prices on drugs.
Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North Carolina, the latest drugmaker to expand its presence in the United States amid President Donald Trump's tariff policies.
Roche said Monday it plans to invest up to $550 million and add hundreds of jobs over the next five years at its Indianapolis-based diagnostics unit.
The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that could change if certain yet-unspecified policies are implemented that could “harm our industry’s ability to operate and innovate in America.
RHHBY unveiled plans to invest over $700 million in a new 700,000-square-foot, state-of-the-art drug manufacturing facility in Holly Springs, NC. Through this new plant, the company intends to support its pipeline of next-generation obesity drugs for Genentech,
President Donald Trump's executive order mandates drugmakers to lower prices to match those in affluent nations, threatening Roche's $50 billion U.S. investment plan. While the policy may be tough to implement,
Roche committed $50 billion in U.S. manufacturing funds, with which it will construct at least four new facilities.
Feedback